DiaGyn · raw details

DiaGyn is developing a wide range of solutions targeting unmet needs in the area of womens health, integrating drug development and molecular genomics with personalized therapeutic approaches. The company is focused on addressing BRCA1/2 mutations in ovarian and breast cancer using a treatment strategy based on nanoparticle technology. DiaGyn has developed DIG790 for the treatment of patients with advanced epithelial ovarian cancer (EOC). The innovative product comprises 100 nm mesoporous silica nanoparticles (MSNP) loaded with the antineoplastic docetaxel and capped with the cyclic oligosaccharide cyclodextrin. The cyclodextrin cap linked to the silica particles prevents the uncontrolled release of chemotherapy from the pores before arrival at the intended site. The special design of DiaGyns nanoparticles involves a sensitive linker that selectively senses the high levels of -galactosidase and low pH encountered in the surrounding EOC cells, releasing the drug into the malignant cells while leaving normal tissues largely unaffected. DiaGyn is a subsidiary of Goldman Hirsh Partners.